These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 27597816)
1. Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration. Ramsay RR; Majekova M; Medina M; Valoti M Front Neurosci; 2016; 10():375. PubMed ID: 27597816 [TBL] [Abstract][Full Text] [Related]
3. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Youdim MB; Fridkin M; Zheng H Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213 [TBL] [Abstract][Full Text] [Related]
4. ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy. Marco-Contelles J; Unzeta M; Bolea I; Esteban G; Ramsay RR; Romero A; Martínez-Murillo R; Carreiras MC; Ismaili L Front Neurosci; 2016; 10():294. PubMed ID: 27445665 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of BACE1, MAO-B, cholinesterase enzymes, and anti-amyloidogenic potential of selected natural phytoconstituents: Multi-target-directed ligand approach. Chowdhury S; Kumar S J Food Biochem; 2021 Jan; 45(1):e13571. PubMed ID: 33249607 [TBL] [Abstract][Full Text] [Related]
6. N-alkylpiperidine carbamates as potential anti-Alzheimer's agents. Košak U; Strašek N; Knez D; Jukič M; Žakelj S; Zahirović A; Pišlar A; Brazzolotto X; Nachon F; Kos J; Gobec S Eur J Med Chem; 2020 Jul; 197():112282. PubMed ID: 32380361 [TBL] [Abstract][Full Text] [Related]
7. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. Naoi M; Maruyama W; Akao Y; Yi H; Yamaoka Y J Neural Transm Suppl; 2006; (71):67-77. PubMed ID: 17447417 [TBL] [Abstract][Full Text] [Related]
8. Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. Esteban G; Allan J; Samadi A; Mattevi A; Unzeta M; Marco-Contelles J; Binda C; Ramsay RR Biochim Biophys Acta; 2014 Jun; 1844(6):1104-10. PubMed ID: 24642166 [TBL] [Abstract][Full Text] [Related]
9. Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies. Binda C; Milczek EM; Bonivento D; Wang J; Mattevi A; Edmondson DE Curr Top Med Chem; 2011 Nov; 11(22):2788-96. PubMed ID: 22039878 [TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. Youdim MBH J Neural Transm (Vienna); 2018 Nov; 125(11):1719-1733. PubMed ID: 30341696 [TBL] [Abstract][Full Text] [Related]
11. Identification of Butyrylcholinesterase and Monoamine Oxidase B Targeted Ligands and their Putative Application in Alzheimer's Treatment: A Computational Strategy. Jabir NR; Rehman MT; Tabrez S; Alserihi RF; AlAjmi MF; Khan MS; Husain FM; Ahmed BA Curr Pharm Des; 2021; 27(20):2425-2434. PubMed ID: 33634754 [TBL] [Abstract][Full Text] [Related]
12. Potential of Tryptamine Derivatives as Multi-Target Directed Ligands for Alzheimer's Disease: AChE, MAO-B, and COX-2 as Molecular Targets. Asghar S; Mushtaq N; Ahmed A; Anwar L; Munawar R; Akhtar S Molecules; 2024 Jan; 29(2):. PubMed ID: 38276568 [TBL] [Abstract][Full Text] [Related]
13. Resveratrol Analogues as Dual Inhibitors of Monoamine Oxidase B and Carbonic Anhydrase VII: A New Multi-Target Combination for Neurodegenerative Diseases? Carradori S; Fantacuzzi M; Ammazzalorso A; Angeli A; De Filippis B; Galati S; Petzer A; Petzer JP; Poli G; Tuccinardi T; Agamennone M; Supuran CT Molecules; 2022 Nov; 27(22):. PubMed ID: 36431918 [TBL] [Abstract][Full Text] [Related]
14. Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer's disease therapy. Youdim MBH J Neural Transm (Vienna); 2022 Jun; 129(5-6):715-721. PubMed ID: 35190910 [TBL] [Abstract][Full Text] [Related]
15. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches. Duarte P; Cuadrado A; León R Handb Exp Pharmacol; 2021; 264():229-259. PubMed ID: 32852645 [TBL] [Abstract][Full Text] [Related]
16. Indole alkaloids of Psychotria as multifunctional cholinesterases and monoamine oxidases inhibitors. Passos CS; Simões-Pires CA; Nurisso A; Soldi TC; Kato L; de Oliveira CM; de Faria EO; Marcourt L; Gottfried C; Carrupt PA; Henriques AT Phytochemistry; 2013 Feb; 86():8-20. PubMed ID: 23261030 [TBL] [Abstract][Full Text] [Related]
17. Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities. Mazumder MK; Borah A; Choudhury S Med Hypotheses; 2020 Apr; 137():109544. PubMed ID: 31954292 [TBL] [Abstract][Full Text] [Related]
18. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. Mallajosyula JK; Kaur D; Chinta SJ; Rajagopalan S; Rane A; Nicholls DG; Di Monte DA; Macarthur H; Andersen JK PLoS One; 2008 Feb; 3(2):e1616. PubMed ID: 18286173 [TBL] [Abstract][Full Text] [Related]
19. Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases. Mathew B; Parambi DGT; Mathew GE; Uddin MS; Inasu ST; Kim H; Marathakam A; Unnikrishnan MK; Carradori S Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900177. PubMed ID: 31478569 [TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. Nagatsu T; Sawada M J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]